All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Asia EquityAsia IPOs

Banks dive into biotech as first IPO wave hits HK

Pharmaceutical 230x150

The Hong Kong Stock Exchange’s revolutionary change to its listing regime for biotechnology companies is starting to pay off, as the pipeline of pre-revenue firms looking to go public builds. But there are numerous challenges ahead, not least in understanding the sector and the risks involved. Jonathan Breen reports.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree